Active Filter(s):
Details:
Under the agreement, Alchemab and MDC will evaluate antibodies using innovative technologies, including the use of high content imaging, high resolution microscopy, spatial transcriptomics to assess endpoints using induced pluripotent stem cell derived neuronal & glial cells.
Lead Product(s): Human Monoclonal Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Alchemab
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2022